About ORPHELIA Pharma
ORPHELIA Pharma is a company based in Paris (France) founded in 2007 by Hugues Bienayme was acquired by Orphalan in November 2025. ORPHELIA Pharma has raised $4.49 million across 2 funding rounds from investors including Bpifrance, Orphalan and Octalfa. ORPHELIA Pharma offers products and services including KIZFIZO. ORPHELIA Pharma operates in a competitive market with competitors including Ironwood Pharma, Marinus Pharma, Arvelle Therapeutics, VeraDermics and Lipum, among others.
- Headquarter Paris, France
- Founders Hugues Bienayme
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Orphelia Pharma Sas
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ORPHELIA Pharma
ORPHELIA Pharma offers a comprehensive portfolio of products and services, including KIZFIZO.
Pediatric formulation of temozolomide for treating Wilms tumor and other cancers
Funding Insights of ORPHELIA Pharma
ORPHELIA Pharma has successfully raised a total of $4.49M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $4.49 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ORPHELIA Pharma
ORPHELIA Pharma has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Bpifrance, Orphalan and Octalfa.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Octalfa is engaged in creating and supporting innovative companies.
|
Locked | Locked | Locked | |
|
CEMAG Care is focused on women's health and reproductive solutions.
|
Locked | Locked | Locked | |
|
Corporate consultancy, advisory, and funding services are provided to businesses.
|
Locked | Locked | Locked |
Investor details for ORPHELIA Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ORPHELIA Pharma
Investment portfolio details for ORPHELIA Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ORPHELIA Pharma
Detailed financials for ORPHELIA Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Orphelia Pharma Comparisons
Peer comparison for ORPHELIA Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ORPHELIA Pharma
ORPHELIA Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, Marinus Pharma, Arvelle Therapeutics, VeraDermics and Lipum, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics to treat seizure disorders
|
|
| Locked | Locked | Locked |
Small molecule therapies are developed for partial-onset seizures treatment.
|
|
| Locked | Locked | Locked |
Drug-delivery platforms for pediatric wart treatments are developed.
|
|
| Locked | Locked | Locked |
Developer of antibody to treat juvenile idiopathic arthritis
|
|
| Locked | Locked | Locked |
Medicines for chronic diseases in children are developed and provided.
|
Detailed competitors of ORPHELIA Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Orphelia Pharma
Complete news archive for ORPHELIA Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ORPHELIA Pharma
ORPHELIA Pharma was founded in 2007 and raised its 1st funding round 11 years after it was founded.
ORPHELIA Pharma is headquartered in Paris, France.
Hugues Bienayme is the current CEO of ORPHELIA Pharma. They have also founded this company.
ORPHELIA Pharma is a funded company, having raised a total of $4.49M across 2 funding rounds to date.
Orphelia Pharma was founded in 2007 and is based in Paris, France, where focus is placed on developing treatments for pediatric neurology, oncology, and hematological malignancies. The lead candidate, ORP 010, is under review by the EMA for a rare hematological condition. Additional programs include ORP 005 in clinical development and ORP 009 in preclinical stages. An antiepileptic drug, vigabatrin, has been formulated for childhood epilepsy.
ORPHELIA Pharma's top competitors include Ironwood Pharma, Marinus Pharma and Castle Creek Biosciences.
ORPHELIA Pharma offers KIZFIZO.
ORPHELIA Pharma has 4 investors. Key investors include Bpifrance, Orphalan, Octalfa, and CEMAG Care.